^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LMP744

    i
    Other names: LMP744, LMP 744, NSC 706744, NSC706744, MJ-III-65, LMP-744
    Associations

    News

    Trials
    Company:
    Gibson Oncology, National Cancer Institute, Purdue University
    Drug class:
    Topoisomerase I inhibitor, MYC inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=36, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=53 --> 36
    Trial completion • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    LMP744
    2years
    Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    LMP744